Literature DB >> 2682627

Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

S Agrawal1, T Ikeuchi, D Sun, P S Sarin, A Konopka, J Maizel, P C Zamecnik.   

Abstract

Antisense oligodeoxynucleotides, both the phosphorothioate analogues and unmodified oligomers of the same sequence, inhibit replication and expression of human immunodeficiency virus already growing in tissue cultures of MOLT-3 cells with much greater efficacy than do mismatched ("random") oligomers and homooligomers of the same length and with the same internucleotide modification. This preferential inhibitory effect is elicited in as short a time as 4-24 hr postinfection. Likewise, antisense oligomers exhibit greater inhibitory effects on human immunodeficiency virus in chronically infected cells than do mismatched oligomers and homooligomers. Phosphorothioate antisene oligomers are up to 100 times more potent than unmodified oligomers of the same sequence in these inhibitory assays. These results, in major respects, confirm and extend those recently published by Matsukura et al. [Matsukura, M., Zon, G., Shinozuka, K., Robert-Guroff, M., Shimada, T., Stein, C. A., Mitsuza, H., Wong-Staal, F., Cohen, J. S. & Broder, S. (1989) Proc. Natl. Acad. Sci. USA 86, 4244-4248]. They also point out the importance of computer analysis of sequences though to be random but that in reality contain significant areas of likely hybridization, either to the viral genome or to the complementary DNA strand synthesized from it. They thus reinforce the concept that specific base pairing is a crucial feature of oligonucleotide inhibition of human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682627      PMCID: PMC298156          DOI: 10.1073/pnas.86.20.7790

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Inhibition of HTLV-III/LAV replication by foscarnet.

Authors:  P S Sarin; Y Taguchi; D Sun; A Thornton; R C Gallo; B Oberg
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

2.  Antisense oligodeoxynucleotides provide insight into mechanism of translation initiation of two Sendai virus mRNAs.

Authors:  K C Gupta
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

3.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

4.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

7.  Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.

Authors:  C C Smith; L Aurelian; M P Reddy; P S Miller; P O Ts'o
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

8.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

9.  Oligodeoxynucleotide stability in subcellular extracts and culture media.

Authors:  E Wickstrom
Journal:  J Biochem Biophys Methods       Date:  1986-09

10.  Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone.

Authors:  P S Sarin; D Sun; A Thornton; W E Müller
Journal:  J Natl Cancer Inst       Date:  1987-04       Impact factor: 13.506

View more
  46 in total

1.  Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients.

Authors:  Kaneez Fatima; Rehan Zafar Paracha; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.

Authors:  E R Kandimalla; A Manning; Q Zhao; D R Shaw; R A Byrn; V Sasisekharan; S Agrawal
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

4.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

6.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

7.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents.

Authors:  R P Iyer; B Uznanski; J Boal; C Storm; W Egan; M Matsukura; S Broder; G Zon; A Wilk; M Koziolkiewicz
Journal:  Nucleic Acids Res       Date:  1990-05-25       Impact factor: 16.971

Review 9.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

Review 10.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.